WEBULL
WebtradeDownload

Why Bavarian Nordic (CPSE:BAVA) Is Back In The Spotlight

Simply Wall St · 1d ago

Bavarian Nordic (CPSE:BAVA) just confirmed a major leadership change, with Tarja Stenvall set to take over as President and CEO on 15 October 2026, succeeding long-serving leader Paul Chaplin.

The leadership announcement comes after a strong 90-day share price return of 16.13% and a 14.63% share price return year to date, although the 1-year total shareholder return declined 3.32% and the 5-year total shareholder return fell 26.19%. Meanwhile, the 3-year total shareholder return improved 44.44%, suggesting momentum has picked up recently even as longer term holders have had a mixed experience.

Scan how Bavarian Nordic compares with other vaccine and pharma players by reviewing our curated list of list of solid balance sheet and fundamentals (205 results).

Bavarian Nordic trades at a hefty discount to both analyst targets and an internal fair value estimate after a solid recent rebound. Is the market prudently cautious about the business, or is it mispricing the setup ahead of a new CEO?

Most Popular Narrative: 19% Undervalued

Bavarian Nordic closed at DKK221, while the most followed narrative pegs fair value at DKK273.33, leaving a sizeable valuation gap that investors are trying to explain.

The company's recent revenue surge and margin strength are heavily anchored in exceptional short-term demand for travel health and public preparedness vaccines, which may be unsustainable as contract wins and outbreak-based orders normalize. This could lead to a flattening or decline in revenues and/or increased volatility in future earnings as pandemic and epidemic fears subside.

See why 33 investors see Bavarian Nordic as 19% undervalued.

The valuation work behind that DKK273.33 figure uses a 5.39% discount rate and assumes broadly flat revenue, softer profit margins and earnings of DKK987.7m by around June 2029. In turn, the narrative assumes Bavarian Nordic trading on a future P/E of 23.5x those projected earnings, which is above the current 11.9x multiple referenced in the narrative and above the 12.0x cited for the GB Biotechs peer group.

Analysts cited in the narrative also expect the share count to shrink by about 1.76% per year over the next three years, which would lift earnings per share if those buybacks materialise. At the same time, there is wide dispersion in earnings expectations, with the most optimistic forecast at DKK1.3b and the most cautious view at DKK616.8m, so the fair value story still depends heavily on which side of that range an investor considers more realistic.

Result: Fair Value of DKK273.33 (UNDERVALUED)

Still, that story can break if new vaccines or regulatory price controls hit Bavarian Nordic’s concentrated portfolio and squeeze the expected earnings path.

Find out about the key risks to this Bavarian Nordic narrative.

Next Steps

Mixed signals around Bavarian Nordic can either spook you or sharpen your thinking. Move quickly, review the data, and weigh the 4 key rewards and 3 important warning signs in 4 key rewards and 3 important warning signs.

Looking for more Bavarian Nordic investment ideas?

If Bavarian Nordic has your attention, do not stop here. The same tools can help you quickly surface other focused opportunities that fit your style and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.